

Supplementary Table 1 – Description of medicine innovative appraisal, ordered by date of publication on AIFA's website – Last access 31 July 2020

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
1	daratumumab	H	Adult	Yes	July 2017	Not innovative	Important	Moderate	Low	<i>Although multiple myeloma is a rare disease (prevalence does not exceed 5 / 10,000) AIFA evaluated this medicine in a setting of non-rare disease</i>
2	glecaprevir and pibrentasvir	Non-Onco	Adult	No	July 2017	Fully innovative	Important	Important	Moderate	
3	obeticholic acid	Non-Onco	Adult	Yes	May 2017	Not innovative	Maximum	Poor	Low	
4	baricitinib	Non-Onco	Adult	No	June 2017	Not innovative	Moderate	Poor	High	
5	nusinersen	Non-Onco	Pediatric	Yes	July 2017	Fully innovative	Maximum	Important	Low	
6	palbociclib	S	Adult	No	June 2017	Not innovative	Important	Poor	Moderate	
7	palbociclib	S	Adult	No	June 2017	Conditionally innovative	Moderate	Moderate	Moderate	
8	cenegermin	Non-Onco	Adult	Yes	November 2017	Fully innovative	Important	Important	Low	
9	ceftazidime / avibactam	Non-Onco	Adult	No	July 2017	Not innovative	Important	Poor	Low	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
10	nivolumab	S	Adult	No	September 2017	Not innovative	Important	N/A	Low	<i>The added therapeutic value in this indication was considered not assessable</i>
11	allogeneic t cells genetically modified	H	Adult	Yes	September 2017	Not innovative	Moderate	Moderate	Very low	
12	daratumumab	H	Adult	Yes	October 2017	Fully innovative	Moderate	Important	Moderate	
13	sofosbuvir/ velpatasvir/ voxilaprevir	Non-Onco	Adult	No	July 2017	Fully innovative	Important	Important	Moderate	
14	adalimumab	Non-Onco	Adult	Yes	November 2017	Conditionally innovative	Important	Moderate	Moderate	
15	lenalidomide	H	Adult	Yes	September 2017	Conditionally innovative	Moderate	Moderate	Moderate	
16	inotuzumab ozagamicin	H	Adult	Yes	October 2017	Conditionally innovative	Moderate	Moderate	Moderate	
17	atezolizumab	S	Adult	No	November 2017	Fully innovative	Important	Moderate	High	
18	bezlotoxumab	Non-Onco	Adult	No	October 2017	Not innovative	Important	Moderate	Low	
19	dinutuximab beta	S	Mixed	Yes	February 2018	Fully innovative	Maximum	Important	Moderate	
20	dinutuximab beta	S	Mixed	Yes	February 2018	Not innovative	Maximum	Important	Very low	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
21	alectinib	S	Adult	No	January 2018	Conditionally innovative	Moderate	Moderate	Moderate	
22	alectinib	S	Adult	No	January 2018	Fully innovative	Moderate	Important	Moderate	
23	nivolumab	S	Adult	No	November 2017	Conditionally innovative	Important	Moderate	Moderate	
24	midostaurin	H	Adult	Yes	December 2017	Fully innovative	Moderate	Important	Moderate	
25	midostaurin	H	Adult	Yes	December 2017	Not innovative	Important	Poor	Low	
26	ibrutinib	H	Adult	Yes	October 2017	Conditionally innovative	Moderate	Moderate	Moderate	
27	dupilumab	Non-Onco	Adult	No	January 2018	Fully innovative	Important	Moderate	High	
28	ocrelizumab	Non-Onco	Adult	No	February 2018	Not innovative	Maximum	Poor	Moderate	
29	letermovir	Non-Onco	Adult	Yes	February 2018	Fully innovative	Moderate	Important	High	
30	avelumab	S	Adult	Yes	January 2018	Conditionally innovative	Important	Moderate	Low	
31	canakinumab	Non-Onco	Mixed	Yes	December 2017	Conditionally innovative	Important	Moderate	Moderate	
32	ibrutinib	H	Adult	Yes	July 2017	Not innovative	Poor	Poor	Moderate	
33	ribociclib	S	Adult	No	November 2017	Conditionally innovative	Moderate	Moderate	Moderate	
34	nivolumab	H	Adult	Yes	July 2017	Conditionally innovative	Maximum	Moderate	Low	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
35	niraparib	S	Adult	Yes	January 2018	Conditionally innovative	Important	Moderate	Moderate	
36	regorafenib	S	Adult	No	February 2018	Conditionally innovative	Maximum	Moderate	High	
37	emicizumab	Non-Onco	Mixed	Yes	June 2018	Fully innovative	Moderate	Important	Low	
38	ethyl telotristat	S	Adult	Yes	January 2018	Not innovative	Important	Poor	Moderate	
39	liposomal daunorubicin hydrochloride / cytarabine	H	Adult	Yes	November 2018	Fully innovative	Moderate	Important	Moderate	
40	pembrolizumab	S	Adult	No	May 2019	Fully innovative	Moderate	Important	High	
41	tocilizumab	Non-Onco	Adult	Yes	July 2018	Conditionally innovative	Moderate	Moderate	Moderate	
42	daratumumab	H	Adult	Yes	October 2017	Fully innovative	Moderate	Important	Moderate	
43	cladribine	Non-Onco	Adult	No	April 2018	Not innovative	Moderate	Poor	Very low	
44	lutetium oxodotreotide	S	Adult	Yes	March 2018	Fully innovative	Important	Important	Low	
45	darvadstrocel	Non-Onco	Adult	Yes	April 2019	Not innovative	Moderate	Poor	Low	
46	cysteamine	Non-Onco	Mixed	Yes	January 2018	Not innovative	Poor	Moderate	Very low	
47	obinutuzumab	H	Adult	Yes	March 2018	Not innovative	Poor	Poor	Moderate	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
48	pembrolizumab	S	Adult	No	June 2018	Conditionally innovative	Important	Moderate	High	
49	pembrolizumab	H	Adult	Yes	November 2017	Conditionally innovative	Maximum	Moderate	Low	
50	pertuzumab	S	Adult	No	November 2018	Not innovative	Moderate	Poor	Moderate	
51	tisagenlecleucel	H	Mixed	Yes	January 2019	Fully innovative	Important	Important	Moderate	
52	tisagenlecleucel	H	Adult	Yes	January 2019	Fully innovative	Important	Important	Low	
53	burosumab	Non-Onco	Pediatric	Yes	December 2018	Conditionally innovative	Important	Moderate	Low	
54	durvalumab	S	Adult	No	March 2019	Fully innovative	Important	Important	Moderate	
55	lenvatinib	S	Adult	Yes	April 2019	Not innovative	Important	Absent	Moderate	
56	brentuximab vedotin	H	Adult	Yes	April 2018	Conditionally innovative	Moderate	Moderate	Moderate	
57	pembrolizumab	S	Adult	No	May 2019	Fully innovative	Important	Moderate	High	
58	pembrolizumab	S	Adult	No	May 2019	Fully innovative	Moderate	Important	Moderate	
59	nivolumab	S	Adult	No	April 2019	Fully innovative	Important	Moderate	High	
60	osimertinib	S	Adult	No	February 2019	Fully innovative	Moderate	Important	Moderate	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
61	acicabtagene ciloleucel	H	Adult	Yes	January 2019	Fully innovative	Important	Important	Moderate	
62	dabrafenib	S	Adult	No	April 2019	Fully innovative	Important	Important	High	
63	trametinib	S	Adult	No	April 2019	Fully innovative	Important	Important	High	
64	doravirina/ lamivudina/ tenofovir disoproxil	Non-Onco	Adult	No	May 2019	Not innovative	Poor	Poor	Moderate	
65	doravirine	Non-Onco	Adult	No	May 2019	Not innovative	Poor	Poor	Moderate	
66	venetoclax	H	Adult	Yes	April 2019	Conditionally innovative	Moderate	Moderate	Moderate	
67	abemaciclib	S	Adult	No	May 2019	Conditionally innovative	Moderate	Moderate	Moderate	
68	caplacizumab	Non-Onco	Adult	Yes	February 2019	Conditionally innovative	Moderate	Moderate	Low	
69	patisiran	Non-Onco	Adult	Yes	November 2018	Fully innovative	Important	Important	Moderate	
70	emicizumab	Non-Onco	Mixed	Yes	October 2019	Conditionally innovative	Moderate	Moderate	Low	
71	metreleptin	Non-Onco	Mixed	Yes	February 2019	Conditionally innovative	Maximum	Moderate	Very low	Ultra-rare disease
72	abiraterone acetate	S	Adult	No	May 2018	Not innovative	Moderate	Poor	Moderate	
73	alirocumab	Non-Onco	Adult	No	November 2019	Not innovative	Moderate	Poor	Moderate	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
74	encorafenib	S	Adult	No	May 2019	Not innovative	Moderate	Poor	Moderate	
75	binimetinib	S	Adult	No	May 2019	Not innovative	Moderate	Poor	Moderate	
76	lanadelumab	Non-Onco	Mixed	Yes	December 2019	Not innovative	Moderate	Poor	Moderate	
77	cerliponase alfa	Non-Onco	Pediatric	Yes	December 2018	Fully innovative	Maximum	Important	Very low	Ultra-rare disease

* according to orphanet

AIFA: italian medicines agency; CTS: technical-scientific committee; H: hematological malignancies; S: solid tumor; onco: oncological disease; non-onco: non oncological disease